What is the success rate of stem cell therapy for Crohn's & IBD?
No general cell-therapy success rate applies across Crohn's disease, ulcerative colitis, luminal disease and perianal fistulas. Review the exact indication, product, comparator, clinical and endoscopic remission, fistula outcomes, steroid use, surgery, adverse events and full follow-up.
What the evidence shows for Crohn's & IBD
Alofisel (darvadstrocel) was an allogeneic adipose-derived MSC product formerly authorised in the EU for selected complex perianal fistulas in adults with Crohn's disease. The European Commission withdrew its marketing authorisation on 13 December 2024, and EMA states that the authorisation is no longer valid. See the EMA Alofisel record. This history must not be presented as current approval or transferred to another product, route or IBD indication.
Am I a candidate? → · Crohn's & IBD: full overview → · Crohn's & IBD cost → · Cost →
Evidence checked against ISSCR, FDA and EMA guidance. See our editorial standards. This is information, not medical advice. Educational information, not medical advice; figures indicative.